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a b s t r a c t
Objective: To evaluate whether cardiovascular risk, risk awareness, and guideline concordant treatment
differ in individuals with versus without epilepsy.
Methods: This was a retrospective cross-sectional study using the National Health and Nutrition
Examination Survey. We included participants 18 years for 2013–2018. We classified participants as
having epilepsy if reporting 1 medication treating seizures. We calculated 10-year atherosclerotic cardiovascular disease (ASCVD) risk using the revised pooled cohort equation. We compared unadjusted and
adjusted risk for participants with versus without epilepsy. We then assessed hypertension and diabetes
disease awareness and control, plus statin guideline-concordance. We assessed mediators for both
ASCVD risk and cardiovascular disease awareness.
Results: Of 17,961 participants, 154 (0.9%) had epilepsy. Participants with epilepsy reported poorer diet
(p = 0.03), fewer minutes of moderate-vigorous activity per day (p < 0.01), and increased frequency of cardiovascular conditions (e.g. coronary heart disease, myocardial infarction, stroke). There was no difference in control of individual examination and laboratory risk factors between groups (A1c, systolic
blood pressure, diastolic blood pressure, high-density lipoprotein, low-density lipoprotein, total cholesterol). However, epilepsy was associated with 52% (95% confidence interval [CI]: 0–130%) increase in
ASCVD risk, which became nonsignificant after adjusting for health behaviors. No single studied variable
(income, Patient Health Questionnaire-9 (PHQ-9), diet, smoking) had a significant indirect effect.
Participants with epilepsy reported increased hypertension awareness which was trivially but significantly mediated by having a routine place of healthcare (indirect effect: 1% absolute increase (95% CI:
0–1%), and they reported increased rates of hypertension treatment and guideline-concordant statin
therapy. Participants with versus without epilepsy reported similar rates of blood pressure control and
diabetes awareness, treatment, and control.
Conclusions: Participants with epilepsy had increased ASCVD risk, despite similar or better awareness,
treatment, and control of individual risk factors such as diabetes and hypertension. Our results suggest
that epilepsy is associated with numerous health behaviors leading to cardiovascular disease, though
the causal pathway is complex as these variables (income, depression, diet, exercise, smoking) generally
served as confounders rather than mediators.
Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).

1. Introduction
⇑ Corresponding author at: Institute of Primary Health Care (BIHAM), University
of Bern, Mittelstrasse 43, 3012 Bern, Switzerland.
E-mail addresses: sterman@umich.edu (S.W. Terman), caroleelodie.aubert@
insel.ch (C.E. Aubert), chloehi@med.umich.edu (C.E. Hill), jskvarce@med.umich.
edu (J. Skvarce), jamesbur@med.umich.edu (J.F. Burke), scott.mintzer@jefferson.edu
(S. Mintzer).

While clinicians focus attention on sudden unexplained death
in patients with epilepsy (SUDEP), large cohorts suggest that cardiovascular diseases cause up to 30–45% of deaths in people with
epilepsy [1–10]. Fortunately, 30% of cardiovascular deaths are

https://doi.org/10.1016/j.yebeh.2021.107878
1525-5050/Published by Elsevier Inc.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2.4. Variables

thought to be preventable [11]. Thus, optimization of cardiovascular risk factors may provide substantial reduction in mortality and
morbidity for people with epilepsy.
Previous cross-sectional surveys have documented increased
rates of diabetes, coronary heart disease, hypertension, and stroke
in patients with epilepsy [12–15]. However, such studies were limited by self-reported outcomes which could misclassify patients.
Only limited literature has compared objective cardiovascular
measurements in people with and without epilepsy [16], and no
prior studies have compared aggregate cardiovascular risk. Furthermore, the causal pathway between epilepsy and cardiovascular disease is currently incompletely defined. For example, in the
general population it has been documented that only 50–70% of
patients with hypertension or diabetes are actually aware of their
diagnosis, and just 10–30% demonstrate risk factor control [17,18].
These issues may be even more problematic in epilepsy because of
possible disparities in access or adherence [19]. Additional possible
mediators between epilepsy and cardiovascular risk may include
poorer health behaviors [20–22], lower socioeconomic status
[19,23,24], or lipid-elevating enzyme-inducing antiseizure medications [25,26].
In this study, we leveraged a large nationally representative
survey to compare aggregate calculated cardiovascular risk in people with versus without epilepsy. We performed serial modeling
adjusting for a wide range of variables known to influence metabolic risk. We then compared risk factor awareness, guidelineconcordant statin treatment, and risk factor control for people with
versus without epilepsy. Finally, we performed mediation analysis
to assess possible mechanisms underlying relationships between
epilepsy and 10-year atherosclerotic cardiovascular disease
(ASCVD) risk and/or cardiovascular risk awareness.

To identify epilepsy cases, we classified participants according
to whether they responded they were taking at least one medication for epilepsy or seizures. Specifically, respondents were asked
to list all medications prescribed by a healthcare professional
which they have taken in the last 30 days, and provided up to 3
main reasons for using each medication. We confirmed that each
medication with at least one listed reason being epilepsy or seizures was indeed a standard antiseizure medication (ASM). If a
medication was reported for seizures but not actually an ASM by
manual review, we did not count such medications toward our
case definition. We further classified certain ASMs as enzymeinducers (phenobarbital, phenytoin, carbamazepine, and primidone), as these have been associated with hyperlipidemia [25,26].
We collected baseline variables to describe our population.
Demographics included age, sex, race, presence of health insurance, and income to poverty ratio (a family’s income divided by
regional poverty threshold). Given its potential relevance to disease awareness, we included two variables describing access/utilization of routine care: number of non-urgent healthcare
encounters in the past year, and whether participants reported a
routine place of non-urgent care. We included other general health
conditions to describe our population including those related to
cardiopulmonary functioning. Participants reported whether a
doctor has ever told them they have a variety of conditions including asthma, cancer, chronic obstructive pulmonary disease, and
thyroid disease. Participants also completed the Patient Health
Questionnaire-9 (PHQ9) to evaluate depression at the time of the
survey [27] which we include due to depression’s relationship with
the metabolic syndrome [28,29]. Other variables included overall
self-rated health (5-point Likert scale: excellent to poor), body
mass index (kg/m2; both weight and height were taken from objective measurements by the NHANES examination team, not selfreported), and number of ASMs.
Information collected regarding cardiovascular risk factors consisted of behaviors, conditions, physical examination findings, and
laboratory parameters. Behaviors included self-rated dietary
healthfulness (5-point Likert scale: excellent to poor), minutes of
moderate to vigorous work or recreational activity per day [30],
current smoking, and alcoholic drinks per week. Cardiovascular
conditions included whether each participant reported that a doctor had previously diagnosed them with hypertension, coronary
heart disease, congestive heart failure, myocardial infarction, or
stroke. Additionally, similar to what has been done in prior
NHANES studies [17], participants were categorized as having
hypertension or diabetes if (1) they reported taking at least one
prescription medication for either condition, (2) they reported a
physician had previously diagnosed them with the condition, or
(3) NHANES measurements suggested the diagnosis (hypertension:
of up to 3 readings, average systolic blood pressure (SBP) 140 mm
Hg (130 mm Hg if diabetes) or average diastolic blood pressure
(DBP) 90 mm Hg (80 mm Hg if diabetes); diabetes: A1c 6.5%
[31]). Additional laboratory risk factors included high-density
lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) collected for those with a morning fasting blood
draw, and total cholesterol. We calculated 10-year ASCVD risk
(0–100%) for nonfatal myocardial infarction, death from coronary
heart disease, or fatal or nonfatal stroke using the updated pooled
cohort equation [32]. Variables and an example calculation are
depicted in Supplemental table e-1.
We assessed cardiovascular risk factor awareness, treatment,
and control as follows for hypertension and diabetes [17]. Awareness was defined as a participant reported that either (1) a doctor
had previously diagnosed him/her with the condition, or (2) they
reported at least one prescription medication for the condition.

2. Methods
2.1. Study design and dataset
This was a cross-sectional analysis of the National Health and
Nutrition Examination Survey (NHANES) using data collected from
2013-2018. NHANES is a long-standing semi-annual crosssectional study run by the Centers for Disease Control and Prevention (https://wwwn.cdc.gov/nchs/nhanes/default.aspx). Its goal is
to understand broad trends in health and nutrition in the United
States. NHANES samples 5000–10,000 non-institutionalized individuals from 15 counties across the US each year, and oversamples
certain individuals (over 60 years old, African Americans, Hispanics) selected from the US Census to ensure it is nationally representative. It uses complex, stratified, multistage probability cluster
sampling and collects data including respondents’ prescribed medications and health conditions.
2.2. Procedures involving human subjects
This study was deemed exempt by the University of Michigan
Institutional Review Board, given use of publicly available deidentified datasets.
2.3. Participant selection
We included participants at least 18 years old to focus on
adults, and because NHANES does not collect information on smoking in younger participants. Smoking is required to calculate
ASCVD risk. Note that while NHANES does inform the total number
of ASMs taken by each participant, the dataset does not provide
details regarding chronicity or refractoriness of epilepsy.
2
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We compared ASCVD risk between participants with and without epilepsy using survey-weighted linear regressions. We logtransformed ASCVD risks, as untransformed risk was rightskewed with heteroskedasticity across predictors and deciles of
predicted ASCVD. Given the log-transformed outcome, we presented the percentage change in ASCVD risk for each 1-unit
increase of each covariate, which was calculated as (ecoefficient  1) * 100%. Our analysis consisted of 4 serial models. Model 1
was unadjusted, only including the binary variable epilepsy. Model
2 was adjusted for relevant variables not included in ASCVD risk
calculation: diet, activity, being on an enzyme-inducing ASM, body
mass index (BMI), depression severity (PHQ-9), and stroke. Model
3 included Model 2’s variables in addition to demographics (age,
sex, and race) and smoking which are included in ASCVD risk calculation. We performed a fourth sensitivity analysis including all of
Model 3’s variables, in addition to family income to poverty ratio;
this variable was added in a separate model due to more missing
data in that variable. Missing data were handled by list-wise
deletion.
We used survey-weighted chi-squared tests to compare awareness, treatment, and control for diabetes and hypertension.
Denominators were either number of participants with the listed
condition, or else number of participants with a statin indication,
depending on the analysis. We also conducted sensitivity analyses
where we modified the denominators as follows. First, we assessed

Treatment was defined as taking at least one prescription medication for the condition (a subset of those classified as being aware of
the condition). Control was defined according to standard
guideline-driven recommendations as SBP <140 mm Hg
(<130 mm Hg if diabetes) and DBP <90 mm Hg (<80 mm Hg if diabetes) [18] and A1c <7% [33]. Indications for a statin included clinical atherosclerotic disease [past myocardial infarction, stroke, or
angina], diabetes, 10-year ASCVD risk 7.5%, or LDL 190 mg/dL)
[34,35]. Lipid guidelines released in 2013 endorsed targeting these
4 particular high-risk groups for statin therapy based on the pooled
cohort equations released that year, rather than prior guidelines
endorsing treatment primarily targeting LDL levels [36]. We used
the updated guidelines in this study because our study population
spans 2013–2018.
2.5. Statistical analyses
For categorical data, we reported raw counts and surveyweighted proportions. For normally distributed continuous data,
we reported survey-weighted means plus standard deviations or
95% confidence intervals (CI). The weights provided in each biennial cycle’s dataset were divided by 3 (the number of interview
cycles we have used: 2013–2014, 2015–2016, 2017–2018), so that
the estimates are nationally representative of the US population
across the 6-year period [37].

Table 1
Population description according to epilepsy status.
Mean (SD; N) or
Raw No./No. non-missing (weighted %)
Epilepsy

Demographics
Age
Male sex
Race

Mexican American
Non-Hispanic black
Non-Hispanic white

Uninsured
Number of non-urgent healthcare encounters in the last
year
Routine place for healthcare
Family income to poverty ratio
Conditions
Number chronic conditionsb
Asthma
Chronic obstructive pulmonary disease
Patient health questionnaire 9 (PHQ9)c
Thyroid disease
Self-rated health
Excellent
Very good
Good
Fair
Poor
Body mass index (kg/m2)
d
Medications
Total number
ASMs for epilepsy
1
2
3
4
Inducing ASMse

Yes (N = 154)

No (N = 17,807)

p-valuea

48.6 (17.9; 154)
77/154 (54%)
19/154 (7%)
31/154 (11%)
68/154 (67%)
15/154 (10%)
4.2 (2.4; 153)

47.0 (17.7; 17,807)
8,566/17,807 (48%)
2,685/17,807 (9%)
3,831/17,807 (11%)
6,449/17,807 (64%)
3,217/17,766 (15%)
2.4 (2.1; 17,775)

0.43
0.28
0.61

0.14
<0.01

144/154 (95%)
2.1 (1.6; 141)

14,585/17,805 (83%)
3.0 (1.7; 15,824)

<0.01
<0.01

3.4 (2.4; 154)
32/154 (22%)
27/148 (20%)
5.2 (5.8; 117)
25/148 (22%)
5/128 (6%)
15/128 (16%)
43/128 (32%)
52/128 (38%)
13/128 (7%)
30.4 (9.0; 137)
5.6 (4.2; 154)
116 (73%)
27 (18%)
7 (4%)
4 (4%)
63/154 (38%)

1.4 (1.5; 17,807)
2,707/17,791 (16%)
1,453/16,889 (8%)
3.2 (4.2; 15,539)
1,853/16,853 (12%)
1,372/15,664 (10%)
3,990/15,664 (31%)
6,489/15,664 (40%)
3,274/15,664 (16%)
539/15,664 (2%)
29.4 (7.1; 16,806)
2.0 (2.8; 17,807)
N/A

<0.01
0.08
<0.01
0.01
0.02
<0.01

34/17,807 (0.3%)

<0.01

a

0.34
<0.01
N/A

p-values were calculated by survey-weighted Chi-squared tests for categorical variables and t-tests for continuous variables.
b
Number of chronic conditions equal the total number of conditions among epilepsy, asthma, chronic obstructive pulmonary disease, congestive heart failure, coronary
disease, hypertension, diabetes, liver disease, thyroid disease, and malignancy.
c
Common interpretation thresholds for depression include 0–4 minimal, 5–9 mild, 10–14 moderate, 15–19 moderately severe, 20–27 severe [32].
d
Total number refers to the total number of prescription medications, which includes antiseizure medications (ASMs). ASMs refers to the total number of medications
participants reported taking to treat seizures, which includes inducing ASMs. Inducing ASMs refers to phenobarbital, phenytoin, carbamazepine, and primidone, regardless of
indication [21].
e
Inducing ASMs include phenobarbital, phenytoin, carbamazepine, and primidone.
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2.6. Data accessibility statement

awareness among those with measurements exceeding objective
diagnostic thresholds (hypertension: SBP 140 (130 mm Hg if
diabetes) or DBP 90 (80 mm Hg if diabetes); diabetes: A1c
6.5%), rather than in everyone with the condition as described
above. We did this because self-report could misclassify participants for the denominator. Second, we assessed control among
those aware of the condition, rather than in everyone with the condition. Third, we assessed awareness among those without prior
clinical cardiovascular disease (coronary heart disease [CHD],
myocardial infarction [MI], stroke), given awareness would be
expected to be increased by secondary prevention efforts.
Finally, to explore mechanisms driving the relationship
between epilepsy and the above outcomes (ASCVD risk, and disease awareness), we performed mediation analyses [38–41]. We
did this because it is plausible that epilepsy may lead to downstream healthy behaviors (i.e. depression or more sedentary lifestyle) which themselves could lead to higher ASCVD risk
(mediation), rather than less healthy behaviors themselves causing
both epilepsy and ASCVD risk (confounding). We explain details in
the Supplemental Methods appendix.
Data were analyzed using SAS 9.4 (Cary, NC), Stata 14.2 (College
Station, TX), and RStudio version 4.0.1.

All datasets are freely available for download at https://wwwn.
cdc.gov/nchs/nhanes/Default.aspx.

3. Results
3.1. Patient population
Our study included 17,961 participants. Of these, 154 (0.9%)
were classified as having epilepsy. Supplemental table e-2 lists
ASMs leading to classification as having epilepsy. Table 1 depicts
participant characteristics for those with and without epilepsy.
The population with epilepsy reported lower family income, a larger number of chronic conditions, worse PHQ-9 scores and selfrated health status, and a higher number of total medications.
There were no significant differences between populations in age,
sex, race, presence of health insurance, or BMI. Seventy-three percent of our population with epilepsy reported ASM monotherapy,
whereas 27% reported ASM polytherapy.

Table 2
Cardiovascular behaviors, conditions, and examination or laboratory risk factors.
Mean (SD), median (IQR), and Na orRaw no./No. non-missing
(weighted %)
Epilepsy

Behavior
Diet

Excellent
Very good
Good
Fair
Poor
Minutes of moderate-vigorous
work or recreational activity
per day
Current smoking
Alcoholic drinks/weekc

Condition
Congestive heart failure
Coronary heart disease
Diabetes
Hypertension
Myocardial infarction
Stroke
Examination or laboratory risk factor
A1c, %
SBP, mm Hg
DBP, mm Hg
HDL, mm Hg
LDL, mg/dLd
Total cholesterol, mg/dL
ASCVD risk, %

pb

Yes (N = 154)

No (N = 17,807)

12/154 (12%)
22/154 (12%)
68/154 (48%)
35/154 (17%)
17/154 (11%)
Mean: 86 (SD: 160)Median: 30
(IQR 0–120)
N = 152
40/154 (25%)
Mean: 1.2 (SD: 3.2)Median: 0
(IQR: 0–0.7)
N = 84

1,447/17,803 (8%)
3,533/17,803 (22%)
7,215/17,803 (41%)
4,467/17,803 (23%)
1,141/17,803 (6%)
Mean: 159 (SD: 210)Median: 75
(IQR: 0–240)
N = 17,702
3,313/17,794 (18%)
Mean: 3.3 (SD: 7.7)Median: 0.5
(IQR: 0–3.7)
N = 10,524

0.03

12/136
11/148
37/154
90/154
17/148
31/147

585/16,873 (2%)
730/16,849 (4%)
2,940/17,807 (12%)
7,805/17,807 (39%)
734/16,887 (3%)
653/16,890 (3%)

<0.01
0.03
<0.01
0.02
<0.01
<0.01

Mean: 5.7% (SD: 0.9%)
N = 16,251
Mean: 123 (SD: 17)
N = 16,397
Mean: 71 (SD: 12)
N = 16,397
Mean: 54 (SD: 17)
N = 16,073
Mean: 112 (SD: 35)
N = 4,965
Mean: 190 (SD: 42)
N = 16,073
Mean: 5.2% (SD: 8.3%)Median: 1.7%
(IQR: 0.4%-6.5%)
N = 15,493

0.39

(12%)
(9%)
(25%)
(53%)
(10%)
(21%)

Mean: 5.8% (SD: 1.4%)
N = 141
Mean: 124 (SD: 19)
N = 133
Mean: 71 (SD: 15)
N = 133
Mean: 52 (SD: 16)
N = 137
Mean: 114 (SD: 30)
N = 38
Mean: 183 (SD: 35)
N = 137
Mean: 6.1% (SD: 8.2%)Median: 2.5%
(IQR: 0.7%-7.3%)
N = 127

a

<0.01

0.06
<0.01

0.79
0.95
0.17
0.73
0.09
0.048b

Continuous variables with right-skew are also displayed with median (IQR).
p-values were calculated by survey-weighted Chi-squared tests or survey-weighted t-test for difference of means. The except was for ASCVD risk; given substantial rightskew, ASCVD risk was compared via a survey-weighted regression using log (ASDCVD) as the outcome.
c
Number of alcoholic drinks per week was calculated as follows. If participants reported <12 drinks/lifetime then they were coded as 0. Otherwise, participants answered
how many days they drink per week, month, and/or year, and how many drinks they consumed on a given day of drinking. Number of drinks per day was multiplied by the
provided timeframe to calculate average number of drinks per week.
d
LDL sample size was reduced because this laboratory variable was only collected for participants attending the morning session due to the need for a fasting sample.
b
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the relationship between epilepsy and increased log(ASCVD risk).
Epilepsy did not exert a significant direct effect on log(ASCVD),
which was expected given it was nonsignificant in adjusted models
in Table 3. Epilepsy did not exert a significant indirect effect
through any of the studied variables (Table 4). While most CI
demonstrated reasonable precision, the indirect effect of PHQ-9
had an especially wide CI limiting interpretation. While the direct
effect of epilepsy had a wide CI, the point estimates for the direct
effect of epilepsy on log(ASCVD) (ranging from a 67–76% relative
increase in ASCVD) were all greater than the point estimates for
any given potential mediator (ranging from 7% to 2%).

3.2. Health behaviors, cardiovascular conditions, and physical
examination, and laboratory risk factors
The population with epilepsy had worse health behaviors
including poorer self-rated diet and less daily moderate-vigorous
activity, though fewer weekly alcoholic drinks (Table 2). Although
the population with epilepsy reported higher rates of all cardiovascular conditions, there were no significant differences between the
two groups in most examination and laboratory risk factors (A1c,
blood pressure, and cholesterol). However, participants with epilepsy demonstrated higher aggregate ASCVD risk (p = 0.048). Participants with epilepsy had a median 2.5% 10-year ASCVD risk
(interquartile range [IQR]: 0.7%-7.3%) compared with participants
without epilepsy who had a median 1.7% ASCVD risk (IQR: 0.4%6.5%). Fig. 1 depicts the distribution for ASCVD risk, along with distributions for SBP, DBP, HDL, and LDL.
Table 3 displays serial regressions regarding the association
between epilepsy and log(ASCVD risk). In the unadjusted model
(Model 1), participants with epilepsy had a 52% (95% CI: 0%130%) relative increased ASCVD risk. This relationship was attenuated in adjusted Models 2 and 3.
We then tested whether selected behavioral variables which
differed between those with versus without epilepsy mediated

3.3. Awareness, treatment, risk factor control, and guideline
concordance
Participants with epilepsy demonstrated the same or better
rates of awareness, treatment, and control across hypertension,
diabetes, and statin use (Table 5). For example, among participants
classified as having hypertension, 97% versus 84% of participants
with versus without epilepsy reported awareness of their hypertension (p < 0.01). Similarly, among participants classified as having hypertension, 83% of participants with epilepsy versus 58% of
participants without epilepsy reported treatment for hypertension

Fig. 1. Distribution of examination and laboratory risk factors stratified by epilepsy: Histograms for the following risk factors with superimposed distributions for people
with epilepsy (grey) and people without epilepsy (white). (A) systolic blood pressure [SBP], (B) diastolic blood pressure [DBP], (C) high-density lipoprotein (HDL), (D) lowdensity lipoprotein [LDL], (E) 10-year atherosclerotic disease [ASCVD] risk. This figure shows that each of the 5 individual risk factors (A–E) was relatively normally
distributed other than some right skew, and generally has substantial overlap between the groups with versus without epilepsy. Table 2 lists the p-values from surveyweighted t-tests comparing groups from (A–E) which are all >0.05. (F) Shows that ASCVD scores were highly right-skewed necessitating our log-transformation when
comparing groups (p = 0.048). (F) Demonstrates substantial graphical overlap between groups, though the group with epilepsy had scores which were right-shifted compared
with the group without epilepsy explaining this significant difference.
5
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Table 3
Predictors of ASCVD risk.
% change in ASCVD risk per 1-unit change in covariatea (95% CI)
Total N = 17,961

Model 1
N = 15,620

Model 2
N = 13,616

Model 3b
N = 13,616

Epilepsy
Diet

52% (0–130%)

5% (22% to 43%)
Reference group
17% (33% to 3%)
33% (43% to 20%)
36% (47% to 24%)
42% (54% to 26%)
4% (5% to 3%)

17% (6% to 47%)
Reference group
2% (3% to 7%)
13% (6–19%)
18% (13–24%)
21% (12–31%)
0% (0–0%)

25% (13% to 79%)
4% (3% to 5%)
0% (1% to 1%)
15% (5–25%)
–
–
–
–

8% (28% to 18%)
3% (3–3%)
0% (0–1%)
16% (6–26%)
145% (143–147%)
269% (258–281%)
74% (69–80%)
154% (147–161%)

Excellent
Very good
Good
Fair
Poor
Hours of moderate-vigorous work or
recreational activity per day
Inducer ASM
Body mass index (kg/m2)
PHQ-9
Stroke
Age, per decade
Male sex
Non-Hispanic black
Smoking

–
–
–
–
–
–
–
–

a
Because 10-year ASCVD risk was right-skewed with heteroskedasticity, we used log(10-year ASCVD risk) as the outcome for each linear regression in this table.
Interpretation of a logged outcome is therefore a relative percentage change in ASCVD scores for each 1-unit step in covariate, rather than an absolute change in ASCVD risk
for each 1-unit step. Each model was adjusted for all variables with a value in the model’s column.
b
We reran Model 3 including family income to poverty ratio. Listed coefficients were nearly identical, N = 12,357, and the coefficient for income to poverty ratio was 2
(95% CI 3 to 1) suggesting a small correlation between higher income and lower ASCVD.

(p < 0.01). There was no significant difference in rates of hypertension control. No significant differences were observed for each
respective estimate for diabetes. Rates of guideline-concordant statin use were higher for participants with epilepsy (68%) compared
to those without epilepsy (45%) (p < 0.01). We illustrate these findings in Fig. 2 which displays each outcome and comparison using
bar charts with 95% Cis.
Among participants fulfilling blood pressure criteria for hypertension (sensitivity definition), participants with epilepsy were
more likely to be aware of their hypertension diagnosis (p = 0.01;
Supplemental table e-3, left half). Among participants aware of a
hypertension diagnosis, rates of control were no different
(p = 0.64; Supplemental table e-3, right half). No significant differences were observed for either awareness or control using similar
denominators for diabetes.
Because awareness may result from counseling following a clinical ASCVD event, we then restricted to those without known cardiovascular disease (coronary heart disease, myocardial infarction,
or stroke). Among those with hypertension, participants with epilepsy (48/51; 94%) demonstrated greater hypertension awareness
than those without epilepsy (5,293/6,430; (83%) (p = 0.02). Among
those with diabetes, there was no significant difference in awareness between those with (17/17; 100%) versus without
(1,968/2,283; 87%) epilepsy (p = 0.29).
We hypothesized that the association between epilepsy and
increased hypertension awareness, among those with hypertension, could be mediated by greater outpatient encounters. This is
because participants with epilepsy could seek care more frequently
for numerous chronic conditions leading to greater chance for
hypertension detection and subsequent awareness. As per Table 4,
there was a significant direct effect of having epilepsy on hypertension awareness; epilepsy increased the probability of being aware
of the diagnosis by 10% or 12%. While there was a significant path
from epilepsy to hypertension awareness mediated by having a
routine place of care, this indirect effect was small (an absolute
1% increase in hypertension awareness mediated by having a routine place of care) and there was no significant mediation via number of non-urgent health encounters.

4. Discussion
In a large nationally representative sample, we found that participants with epilepsy had similar control of individual examination and laboratory risk factors (blood sugar, blood pressure,
cholesterol) compared to participants without epilepsy. However,
when risk factors were considered in aggregate, participants with
epilepsy carried a 52% relatively high overall cardiovascular risk.
This difference was no longer significant after adjusting other
patient factors such as health behaviors and demographics. This
increase in overall cardiovascular risk was consistent with participants reporting more frequent physician diagnoses across cardiovascular conditions. However, we also found that participants
with epilepsy were in general at least as likely as participants without epilepsy to be aware of diabetes and hypertension diagnoses,
and were even more likely than participants without epilepsy to
receive guideline-concordant statin treatment.
Our initial hypothesis was that participants with epilepsy
would demonstrate worse cardiovascular risk profiles (including
both worse health behaviors, and worse control of other clinical
risk factors) along with poorer awareness of cardiovascular conditions. This hypothesis was informed by several pieces of prior evidence: previous cross-sectional surveys documented 1) increased
rates of self-reported diabetes, hypertension, coronary disease,
and stroke [12–15], 2) worse health behaviors [21,22], 3) disparities in access to care which could interfere with adequate risk factor control [19], and 4) certain enzyme-inducing antiseizure
medications may elevate lipids in people with epilepsy [25]. Our
findings partially support these hypotheses. We did find higher
self-reported rates of cardiovascular conditions (Table 2), and that
participants with epilepsy accordingly demonstrated higher 10year predicted cardiovascular risk. However, our findings do not
support that worse disease awareness or inadequate medical treatment underlies this relationship. In fact, our study found that 1)
among participants with hypertension, those with epilepsy
demonstrated increased awareness of their condition and higher
rates of treatment than those without epilepsy, 2) among participants exceeding blood pressure guidelines, those with epilepsy
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Table 4
Mediation analyses.
Effect from mediation analysis (95% CI)a
Potential mediator

Outcome

Pop.

N

Direct effect of epilepsy on
the outcome

Indirect effect of epilepsy on the outcome through
the potential mediator

Income to poverty ratio
PHQ-9
Dietc
Smoking
Number of non-urgent
health encounters
Having a routine place of
care

Log(ASCVD)
Log(ASCVD)
Log(ASCVD)
Log(ASCVD)
Hypertension
awareness
Hypertension
awareness

All
All
All
All
Participants with
hypertension
Participants with
hypertension

12,990
12,990
12,990
12,990
7873

76% (66%
76% (66%
67% (65%
76% (66%
+10% (+3%

7% (30% to 11%)
2% (92% to 938%)
0% (4% to 5%)
2% (10% to 28%)
+1% (18% to 10%)

7873

+12% (+6% to +16%)

to 750%)
to 750%)
to 812%)
to 750%)
to +20%)

1% (0% to +1%)

b
The direct effect is the predicted increase in the outcome due to having epilepsy. The indirect effect is the predicted increase in the outcome due to having epilepsy, as a
result of epilepsy’s influence increasing the potential mediator which in turn influences the outcome. When outcome was log(ASCVD), the effect is (ecoefficient – 1)*100% to
calculate the relative increase in ASCVD related to having epilepsy (direct effect), or the relative increase in ASCVD related to having epilepsy as a result of possible mediation
through the variable in the listed row (indirect effect). When the outcome was hypertension awareness, the effect is the expected change in absolute probability of
hypertension awareness related to having epilepsy (direct) or related to mediation by the variable listed in each row (indirect). Each model was adjusted for initially
hypothesized possible mediators: income to poverty ratio, PHQ-9, being on an inducer, diet, hours of moderate-vigorous activity per day, smoking.
a
We performed models to assess the degree to which the relationship between epilepsy and two different outcomes (1) log(ASCVD), and 2) hypertension awareness) was
mediated by a variety of potential mediators. We initially hypothesized income, depression, enzyme inducer, diet, exercise, and smoking could mediate the relationship
between epilepsy and ASCVD risk. Unadjusted analyses where epilepsy predicted each potential mediator revealed significance  0.01 for income, PHQ-9, inducer, diet, and
exercise). Epilepsy predicted smoking with p = 0.06. We thus selected those variables which were also significant in Table 3’s fully adjusted Model 4 for consideration as
possible mediators (income, PHQ-9, diet, smoking; enzyme-inducing medication and exercise were not possible mediators given their non-significance in Model 4). We then
also assessed whether several variables capturing outpatient care (number of non-urgent healthcare encounters, having a routine place of care) mediated the relationship
between epilepsy and greater hypertension awareness.
c
Diet was entered as a binary variable (at least good diet versus fair/poor).

Table 5
Awareness, treatment, control.
Awarenessa
Epilepsy

Hypertension
Diabetes
Statind

Controlb

Treatment
Epilepsy

Epilepsy

Yes

No

pc

Yes

No

p

Yes

No

pc

87/90 (97%)
34/37 (83%)
N/A

6,583/7,800 (84%)
2,582/2,939 (89%)
N/A

<0.01
0.43
N/A

73/89 (84%)
27/37 (71%)
36/64 (68%)

4,736/7,606 (59%)
1,846/2,940 (61%)
2,299/5,234 (45%)

<0.01
0.34
<0.01

57/90 (65%)
25/37 (57%)
N/A

3,920/7,805 (54%)
1,556/2,940 (54%)
N/A

0.11
0.80
N/A

a
Awareness: numerator/denominator = (Reporting a physician had diagnosed the condition or taking a medication for that condition)/(Participants classified as having the
condition). Participants were classified as having the condition if they reported a physician had diagnosed the condition, reported taking a medication for that condition, or
exceeded examination or laboratory threshold for the condition. Examination or laboratory thresholds were SBP 140 (130 if diabetes) or DBP 90 (80 if diabetes) for
hypertension, or A1c 6.5% for diabetes.
b
Control: numerator/denominator = (Examination or laboratory measurements below control thresholds)/(Participants classified as having the condition). Control
thresholds included SBP < 140 (<130 if diabetes) and DBP < 90 (<80 if diabetes) for hypertension, and A1c < 7% for diabetes.
c
p-values are all from unadjusted survey-weighted chi-squared tests.
d
Statin treatment: numerator/denominator = (Reporting taking a statin)/(Participants for whom guidelines recommend a statin). Guidelines recommend a statin if clinical
ASCVD (self-reported myocardial infarction, angina, or stroke), diabetes and age 40–75, 10-year ASCVD risk 7.5%, or LDL 190 mg/dL).

cant mediators along the pathway from epilepsy to ASCVD risk. In
particular, current smoking was substantially more strongly correlated with ASCVD risk (109–155% relative increase in ASCVD in
serial models) than epilepsy itself (26–58%). This is unsurprising
given smoking is one variable included in ASCVD risk calculation,
and important in the context of prior literature showing increased
rates of smoking in patients with epilepsy [20]. Poor diet, which is
not included in ASCVD calculation, was also associated with an
independent 17–21% relative increase in ASCVD scores in participants with epilepsy and participants with epilepsy reported worse
diet than those without epilepsy.
Our study has several limitations. First, certain variables had
measurement limitations. Our inclusion criteria based on available
data (taking 1 ASM for seizures or epilepsy) may not have captured all participants with epilepsy; participants with wellcontrolled epilepsy may eventually appropriately discontinue their
ASM [42], or else participants may inappropriately not receive an
ASM despite it being indicated (the ‘‘treatment gap”) [43]. However, we believe this is a reasonable definition because identification of epilepsy by self-report has been validated with positive
predictive value of 74% and sensitivity of 84% [44], presence of
an ASM has been shown to substantially improve detection of epi-

were more likely to be aware of their diagnosis, and 3) among participants with an indication for a statin, those with epilepsy
demonstrated higher rates of statin treatment compared with
those without epilepsy. While we initially hypothesized that
increased disease awareness could be mediated by increased
healthcare encounters, our mediation analysis did not confirm this
hypothesis, and thus it is possible that other factors which we did
not capture (e.g. intensity or specialization of care at a given visit,
or patient attentiveness to health given numerous chronic conditions) could mediate this relationship. Thus, increased healthcare
contact alone did not explain the higher disease awareness, and
also was not enough to overcome worse raw ASCVD scores in people with epilepsy.
Our analyses emphasize the central importance of lifestyle
modification and influence of nonmodifiable factors, rather than
a medical treatment gap regarding blood pressure or any particular
laboratory metric. In our study, the nonmodifiable effect of age
(approximately 140–150% relative increase in ASCVD per decade)
dwarfed the effect of epilepsy (approximately 20–30% relative
increase adjusted for demographics). However, other modifiable
factors related to health behaviors such as diet, exercise, and smoking were all significantly related to ASCVD risk, even if not signifi7

S.W. Terman, C.E. Aubert, C.E. Hill et al.

Epilepsy & Behavior 117 (2021) 107878

Fig. 2. Awareness, treatment, control: This figure graphically presents information contained within Table 5. See footnotes in Table 5 for descriptions of variables. The figure
displays 95% confidence intervals around each proportion in addition to each group’s sample size.

lepsy of 5.2%*(1 – 0.06) = 4.9%, to 5.2%*(1.47) = 7.6%, which is a reasonably precise estimate. Our sample size was adequately powered
to detect an unadjusted effect of epilepsy on ASCVD, in addition to,
for example, difference in hypertension and statin-related parameters between groups. Nonetheless, power was likely lower for binary comparisons with smaller sample sizes (i.e. diabetes
awareness, treatment, and control) or certain parameters in our
multi-regression mediation analyses as made transparent by listed
CI. To more fully elucidate the causal pathway, a larger sample size
of patients with epilepsy would be beneficial in future work.
Third, the cross-sectional study design measures associations
but does not determine causation. The dataset does not inform
whether participants developed cardiovascular risk factors before
or after developing epilepsy.
While we are not aware of any other existing dataset with
equally high-quality capture of ASCVD-related variables in an unselected nationally representative population, future work aimed at
further understanding the influence of epilepsy characteristics (i.e.
chronicity and severity) on health behaviors and ASCVD especially
with a larger sample size of patients with epilepsy would be
valuable.

lepsy in research datasets [45], and ASMs are the mainstay of treatment for epilepsy. Other self-reported variables could be measured
with error too; for example, self-reported physical activity has
been shown to overestimate physical activity compared with
accelerometry [30]. However, we have no reason to suspect measurement error differed between our groups, so this is unlikely to
have biased our comparison. Also, NHANES does not contain information regarding epilepsy characteristics such as disease duration
or seizure frequency, severity, or refractoriness (other than number
of ASMs) which could more fully describe our population with epilepsy. Still, because of the dataset’s national representativeness
and essentially absence of selection bias due to rigorous population
sampling methods across 6 years of data, our population with epilepsy’s seizure characteristics are expected to unbiasedly reflect
those of the US population with epilepsy. Additionally, the dataset
contains excellent assessment of confounders which could possibly
influence our main outcome (ASCVD risk), for example objectively
measuring body mass index, lipids, blood pressure, A1c, etc.
Despite some variables being self-reported, NHANES provides
exceptionally detailed information regarding other confounders
(smoking, exercise, diet, cardiovascular conditions, enzymeinducing antiseizure medications, etc.) which otherwise would
have distorted our main comparison had the dataset been rich in
seizure characteristics but lacking in cardiovascular variables.
Second, our modest sample size of 154 participants with epilepsy could have limited power. However, our results suggest
non-significance of epilepsy in Models 2 and 3 for example could
have simply been due to true effect attenuation after adjusting
for our wide range of cardiovascular-related covariates. Model 10 s
relative effect was 52%, whereas Model 2 and 30 s relative effects
were 5% and 17%, respectively, which supports that there is a
meaningful unadjusted relationship, but that when considered
simultaneously the other listed associated factors are more likely
to drive ASCVD scores rather than epilepsy itself. Also, power
was boosted by a large sample without epilepsy (N = 17,807) and
ASCVD being continuous rather than binary. To illustrate this,
given the mean ASCVD risk for the non-epilepsy group was 5.2%,
Model 3 (where the 95% CI around the relative effect of epilepsy
was 6% to + 47%) would suggest CI bands for someone with epi-

5. Conclusions
Participants with epilepsy reported higher rates of cardiovascular diagnoses. Despite similar control of individual cardiovascular
examination or laboratory risk factors, similar or better risk factor
awareness, and greater frequency of healthcare encounters, participants with epilepsy nonetheless demonstrated 52% higher 10-year
predicted cardiovascular risk compared to participants without
epilepsy. This association was attenuated after accounting for
health behaviors, and numerous health behaviors significantly
influenced cardiovascular risk after adjusting for epilepsy even if
they did not mediate the relationship between epilepsy and risk.
Our work only establishes association rather than causation, given
the cross-sectional data without ability to determine whether epilepsy or cardiovascular disease arose first. Our work nonetheless
suggests that to close the gap in cardiovascular risk, clinicians
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could increase interventions targeting health behaviors associated
with risk (rather than cardiovascular pharmacologic treatment
gaps), interventions may need to focus on content of a given
encounter rather than simply frequency of encounters, and future
studies clarifying this complex causal pathway are warranted to
better understand the likely multifactorial driving mechanisms.
Nonetheless, this is not to diminish the importance of continued
efforts intending to improve approaches to seizure-related treatment or treatment of drug-resistant epilepsy, as it is wellrecognized that a pharmacologic treatment gap exists whereby
many patients unfortunately receive under- or delayed treatment
of seizures [43,46].
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